A new national framework progressing access to genomics
The National Framework for Genomics in Cancer Control lays the groundwork for integrating genomics into cancer prevention, diagnosis, treatment, and clinical trials, with a strong focus on equity and access for priority populations. The Framework emphasises priority populations that experience disparities in early detection, treatment access, and survival outcomes. Pancreatic cancer undeniably falls into each of these categories. Unlike other cancers, pancreatic cancer lacks effective early screening tools, ways to identify high-risk individuals enabling earlier intervention, and limited effective treatment options.
Genomics has enormous potential in pancreatic cancer. Enhancing early detection, identifying high-risk individuals, and expanding access to tailored or targeted therapies are examples. Research indicates that approximately 25% of pancreatic cancer patients who undergo molecular profiling have an actionable genetic alteration (Pishvaian et al, Lancet Oncol 2020), meaning they could be matched to targeted therapies that improve outcomes. In addition, ongoing clinical trials are investigating KRAS inhibitors, targeting the most frequently mutated gene in pancreatic cancer, alongside other emerging precision therapies designed to disrupt the genetic drivers of the disease.
Key aspects of the framework we want to highlight are:
- Recognising priority populations in cancer care
A major strength of the framework is its emphasis on priority populations and at-risk groups, including those with low survival rates and limited access to innovative treatments—a category that includes pancreatic cancer patients.
- Alignment with Pankind’s research strategy and investment
The framework’s highlights two critical areas which align with Pankind’s research strategy:
- Early Detection: Integrating genomic testing into national cancer screening programs to enable earlier and more accurate identification of high-risk individuals.
- Diagnosis, Treatment & Clinical Trials: Expanding access to genomics-informed clinical trials and ensuring that pancreatic cancer patients can benefit from precision medicine advancements.
- Elevating awareness and education
The framework acknowledges that awareness and education are critical to ensuring people impacted and healthcare providers understand genomics’ role in cancer care. Pankind supports this, to ensure those impacted by pancreatic cancer have access to clear, reliable information about genomic testing.
Final thoughts
While the framework outlines ambitious goals, many of the actions remain broad in scope, and will require clear implementation strategies.
The framework reinforces the potential for genomics to impact pancreatic cancer detection and treatment. By aligning our advocacy efforts with these national priorities, we can drive real progress for those impacted by the disease. Prioritising pancreatic cancer in national genomics initiatives ensures greater inclusion in research, clinical trials, and funding.
This is a pivotal moment—let’s ensure pancreatic cancer has a seat at the table.